Testing an AI virtual assistant for people with heart failure after hospital discharge
Tests an AI virtual assistant in adults recently discharged with new heart failure.
Plain-language title generated from the registry record
Registry title: Safety of AI-Powered Virtual Assistant in Outpatient Management of Heart Failure
Key facts
- Where
- Stevenage, United KingdomSee the site
Where in United Kingdom
- East and North Hertfordshire NHS TrustStevenage, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- East and North Hertfordshire NHS Trust
- Trial code
- NCT06400927
- Record updated
- 29 July 2024
- Original description
The aim of this pilot randomized study is to examine whether integrating the SIRIO-HF virtual assistant (VA) into the outpatient management of participants recently discharged from hospital with a new diagnosis of heart failure (HF), may reduce the need for regular medical assessment and the healthcare burden, reduce variability in healthcare, and meet with participant satisfaction, without compromising participant safety and overall care quality.Read full original descriptionShow less
Safety of AI-Powered Virtual Assistant in Outpatient Management of Heart Failure: A Randomized Controlled Pilot Study: ASSIST-HF SIRIO
The aim of this pilot randomized study is to examine whether integrating the SIRIO-HF virtual assistant (VA) into the outpatient management of participants recently discharged from hospital with a new diagnosis of heart failure (HF), may reduce the need for regular medical assessment and the healthcare burden, reduce variability in healthcare, and meet with participant satisfaction, without compromising participant safety and overall care quality.
Inclusion: Age ≥ 18 years; Newly diagnosed HF with New York Heart Association class II-III symptoms at discharge.
Exclusion: Known prior history of HF; Alternative diagnosis for symptoms such as chronic obstructive pulmonary disease; Dementia or other cognitive impairment; Severe comorbidities that could affect protocol adherence, in the opinion of the investigator; Currently involved in another interventional clinical trial.